Industry

The first publication confirms the neurotoxic role of HERV-K/HML-2 ENV detected in the cerebrospinal fluid of sporadic ALS patients and the preclinical therapeutic effect of GeNeuro’s anti-HERV-K ENV antibody in neutralizing HERV-K/HML-2 ENV toxicity. The second publication provides a clinically based rationale for the therapeutic use of a specific neutralizing antibody addressing sporadic ALS neuropathology, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Orthopedic Braces & Support, Casting and Splints – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. Global Orthopedic Braces & Support, Casting and Splints Market to Reach US$7.8 Billion by the Year 2026 The market is witnessing an increased demand from the geriatric population, which is very sensitive in … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Topical Drugs Market Size, Share & Trends Analysis Report by Type (Semi-solid, Liquid), by Route Of Administration (Dermal, Ophthalmic), by End-use (Burn Centers, Hospitals & Clinics), by Region, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The global topical drugs market size is expected to reach USD 217.79 billion … [Read more…]

BERWYN, Pa.–(BUSINESS WIRE)–The AscellaHealth Family of Companies, including AscellaHealth, a global healthcare and specialty pharmacy solutions company, and subsidiaries Optime Care and Terebellum, announces its founding sponsorship of the inaugural Gene Therapy and Specialty Pharmacy Awareness Month, September 2022, which was accepted for inclusion in the annual Calendar of Health Observances & Recognition Days, published … [Read more…]

Diagnoses on the rise as U.S. employers see sharp medical spend increases OREM, Utah–(BUSINESS WIRE)–As COVID-19 cases continue gripping the country, skyrocketing medical costs as a result of long COVID pose a significant financial risk not just for patients, but also for buyers of care in the public and private sectors. According to results of … [Read more…]

SHENZHEN, China & ROCKVILLE, Md.–(BUSINESS WIRE)–HighTide Therapeutics, Inc. (“HighTide”), a globally integrated clinical-stage biotechnology company focused on the development of innovative multi-functional therapeutics to address the complex pathophysiology of metabolic and digestive diseases, announced that enrollment was completed ahead of schedule in a Phase 2 study evaluating HTD1801 in patients with type 2 diabetes mellitus … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Ulcerative Colitis Market Forecast – Epidemiology & Pipeline Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 … [Read more…]

 Conference Call to be Held on Thursday, September 8, 2022 at 4:00 p.m. (EDT) DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the closing of its rights offering and the final results thereof. Navidea received aggregate gross … [Read more…]

Nexa3D creates key dental leadership roles in Europe, focused on expanding access to the latest dental technology Bracon Dental joins Nexa3D Dental reseller network, bringing ultrafast dental 3D printing capabilities to the United Kingdom First desktop XiP installation in a dental business signals rising demand for chair-side 3D printing capabilities   VENTURA, Calif.–(BUSINESS WIRE)–Ultrafast industrial … [Read more…]

OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain. Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market potential. IND filing on OK-101 to treat DED planned for Q4 2022, with first human trial designed as Phase 2 trial planned to begin in Q1 … [Read more…]